Dekk-Tec Inc

DEKK-TEC Inc., established in 1983 in New Orleans, LA, is dedicated to the development of novel therapeutic agents for cancer treatment, particularly focusing on advanced oncology and CNS-related solid tumors. The company has successfully advanced several products into Phase II clinical development through collaborations with biotech pharmaceutical firms, leveraging both government and private funding.

With a strong emphasis on innovative technologies, DEKK-TEC's lead investigational agent, DM-CHOC-PEN, possesses the unique ability to cross the blood-brain barrier, offering a significant advantage over traditional therapies. The company is actively engaged in Phase I studies for DM-CHOC-PEN and is in the process of finalizing INDs for additional anticancer agents, positioning itself at the forefront of cancer management solutions.

Generated from the website